PD-1 inhibitor toripalimab approved in US and China. Strong immuno-oncology pipeline. First Chinese PD-1 approved by FDA.

Biologics company with 10+ commercialized drugs. Sintilimab (PD-1) and obesity drug mazdutide. Partnership with Eli Lilly.

Global biotech company. Zanubrutinib (BTK inhibitor) approved in 70+ countries. Strong oncology pipeline with 50+ molecules.

Biotech leader in bispecific antibodies. Ivonescimab beat Keytruda in Phase 3 trial. Global partnership with Summit Therapeutics.

China's largest innovative drug company. Oncology, autoimmune, and metabolic diseases. 60+ innovative drugs in pipeline.